Evogene Ltd. Stock price TEL AVIV STOCK EXCHANGE
Equities
EVGN
IL0011050551
Biotechnology & Medical Research
Sales 2023 | 5.64M 20.76M | Sales 2024 * | 20.3M 74.72M | Capitalization | 37.23M 137M |
---|---|---|---|---|---|
Net income 2023 | -23M -84.66M | Net income 2024 * | -20M -73.62M | EV / Sales 2023 | 7.44 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.83 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98.27% |
Latest transcript on Evogene Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+9.16% | 45.97B | |
+54.14% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |